Ideal candidates for SUPARTZ are patients with knee OA (1) who:
- Have not responded to conservative non-pharmacologic therapy, including physical therapy
- Have not responded to simple analgesics such as acetaminophen
Directions for use
SUPARTZ is administered by intra-articular injections once a week (1 week apart) for a total of 5 injections. Some patients may experience benefit with 3 injections given at weekly intervals. This has been noted in a study in which patients treated with 3 injections were followed for 90 days. (1, 2) Injection of subcutaneous lidocaine or similar local anesthetic may be recommended prior to injection of SUPARTZ.
Recommendations for managing knee OA pain
Contraindications to SUPARTZ include (1)
- Previous allergic reactions to sodium hylaluronate products, including SUPARTZ
- Infections or skin diseases in the area where the injection will be given
- Allergies to products from birds, such as feathers, eggs, and poultry
The safety and effectiveness of SUPARTZ have not been established in pregnant women, lactating women, or children.
- SUPARTZ (package insert). Durham, NC: Bioventus LLC; 2012.
- Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002;41(11):1240-1248.
- Adapted from: American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee 2000. www.rheumatology.org/practice/clinical/guidelines/oa-mgmt.asp. Accessed November 2, 2011.
- Marks R, Penton L. Are foot orthotics efficacious for treating painful medial compartment knee osteoarthritis? A review of the literature. Int J Clin Pract. 2004;58:49-57.
- Mayo Clinic. Osteoarthritis. Treatment and drugs. www.mayoclinic.com/health/osteoarthritis/DS00019/DSECTION=treatments-and-drugs. Accessed November 14, 2012.